Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00431210 · ClinicalTrials.gov registry record · Phase 1
Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
A Phase 1 study of Nasopharyngeal Carcinoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT00431210: Completed Phase 1 study of Nasopharyngeal Carcinoma, sponsored by Dana-Farber Cancer Institute.
NCT00431210 is a Phase 1 study of Nasopharyngeal Carcinoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 28 participants, below the 96-participant average among 7 other Nasopharyngeal Carcinoma trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00431210, a Phase 1 study of Nasopharyngeal Carcinoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the safety of making and giving Epstein-Barr virus (EBV) immunotherapy products to subjects with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other parts of the body. EBV immunotherapy product is made with white blood cells from the participants body that are collected intravenously. This EBV immunotherapy product may stop cancer cells from growing abnormally. EBV immunotherapy products have been used in several research studies for NPC. Information from these studies suggests the EBV immunotherapy products may stop the growth of NPC in some subjects.
Conditions Studied
Interventions
- BIOLOGICAL Epstein-Barr virus-specific adoptive T-cells immunotherapy
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-02 |
| Est. Completion | 2016-01-26 |
| Phase | Phase 1 |
What the finished NCT00431210 record still lists
NCT00431210 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 96-participant average among 7 other Nasopharyngeal Carcinoma trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Nasopharyngeal Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Epstein-Barr virus-specific adoptive T-cells immunotherapy is the first listed.
NCT00431210 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00431210 about?
NCT00431210 is a clinical study titled "Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma". The purpose of this study is to determine the safety of making and giving Epstein-Barr virus (EBV) immunotherapy products to subjects with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other parts of the body. EBV immunotherapy product is made with white blood ce...
What is the current status of trial NCT00431210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2007-02. Estimated completion is 2016-01-26.
What conditions does trial NCT00431210 study?
This clinical trial studies the following conditions: Nasopharyngeal Carcinoma.
What interventions are being tested in trial NCT00431210?
The interventions under investigation include: Epstein-Barr virus-specific adoptive T-cells immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00431210?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00431210 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nasopharyngeal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
ACTIVE NOT RECRUITING · Phase 1
-
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
ACTIVE NOT RECRUITING · Phase 1
-
LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
COMPLETED · Phase 1
-
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
RECRUITING · Phase 2
-
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia